Stocks TelegraphStocks Telegraph
Stock Ideas

Glaukos (GKOS) Stock Turns Bullish After Analyst Upgrade

By Fahim Awan
Published On December 22, 2023 1:34 PM UTC
Glaukos (GKOS) Stock Turns Bullish After Analyst Upgrade

On Thursday, the U.S. market saw a positive trend in the shares of Glaukos Corporation (NYSE: GKOS), which saw a significant rise of 6.92% and conclude the trading day at $85.11. The upward trend in GKOS shares might be linked to an upgrade that was released by analysts the previous day.

The renowned research company JP Morgan gave Glaukos (GKOS) an upgraded rating on Thursday. Analyst firm raised its price target for GKOS from $66 to $91, and upgraded its rating for the stock from “Neutral” to “Overweight”.

Glaukos also said that it will be attending the 42nd Annual J.P. Morgan Healthcare Conference, which will take place in San Francisco, California, on Tuesday, January 9, 2024, at 5:15 p.m. PT.

Furthermore, GKOS’s New Drug Application (NDA) for iDose TR (travoprost intracameral implant) 75 mcg was recently approved by the FDA in the United States. This prostaglandin analog is intended to lower intraocular pressure (IOP) in individuals suffering from open-angle glaucoma (OAG) or ocular hypertension (OHT). It is given as a single dosage per eye.

A unique formulation of travoprost is delivered to the eye in a sustained therapeutic level with iDose TR, an innovative extended-duration intracameral pharmacological therapy. By addressing persistent side effects and patient noncompliance with typical topical glaucoma treatments, the goal is to improve the quality of therapy.

With the FDA’s approval of iDose TR, GKOS has reached a major turning point in its long and inventive history, which began nearly 15 years ago. With its approval, a new era in interventional glaucoma care has begun, offering patients a proactive and dependable method.

According to Glaukos, iDose TR represents a revolutionary medical innovation that might completely alter the way people with open-angle glaucoma and ocular hypertension are treated in the United States.

GKOS is committed to provide cutting-edge treatments for long-term eye conditions, and it thinks iDose TR has the potential to significantly improve the care that Americans with open-angle glaucoma and ocular hypertension get.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph